ClinicalTrials.gg
RecruitingNCT06577519Updated Jul 27, 2026

Efficacy and Safety Study of Vicagrel in Patients With Acute Coronary Syndrome (ACS) Undergoing Percutaneous Coronary Intervention (PCI)

A Phase 3 interventional study of Vicagrel and Clopidogrel in Acute Coronary Syndrome (ACS) Undergoing Percutaneous Coronary Intervention (PCI), sponsored by Jiangsu vcare pharmaceutical technology co., LTD. Recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-07-27.

Sponsored by Jiangsu vcare pharmaceutical technology co., LTD · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Sep 2024; still recruiting 2 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,000
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 185 studies in Acute Coronary Syndrome with a site in China — 56 open to participants now, 63 under way, 3 of them phase 3. Acute Coronary Syndrome · China.

Planned enrollment
48th of 115
1,000 · median 499
Started
2024
with 17 others
Phase 3
14 of 185
3 open now
Primary completion
2026-12
later than 30 of 62 live
Registered
150th of 185
by date
Lead sponsor
4 of 185
Jiangsu vcare pharmaceutical technology co., LTD

Among the 185 studies in Acute Coronary Syndrome with a site in China, this one is the 48th largest by planned enrollment of the 115 interventional ones that give a count, is one of 18 that started in 2024, is one of 14 in phase 3, reaches primary completion later than 30 of the 62 other live ones, and was the 150th registered.

Acute Coronary Syndrome

1,491 studies on the registry are indexed under Acute Coronary Syndrome; 273 are open to participants now.

Browse Acute Coronary Syndrome studies →

Open to participants now

56 of the 185 studies in Acute Coronary Syndrome with a site in China are open now. Recruiting first, the newest first:

50 more — sign in →

All 56 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 196 Acute Coronary Syndrome studies recruiting now, 145 (74%) set no upper age limit and 19 (10%) stop at 75 or younger; 15 take children under 18; 15 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 185 studies in Acute Coronary Syndrome with a site in China, or all of them as a file.
02

Study summary

This is a multi-center, randomized, double-blind, double-dummy, parallel-controled, phase III trial, aiming to evaluate the effectiveness and safety of long-term continuous administration of Vicagrel capsules in ACS patients undergoing PCI.

03

Conditions studied

  • Acute Coronary Syndrome (ACS) Undergoing Percutaneous Coronary Intervention (PCI)
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients between 18 and 80 years old, with no gender restrictions.
  • Patients diagnosed with ACS and scheduled for PCI, including STEMI and NSTE-ACS (UA/NSTEMI).
  • Voluntarily sign the ICF and be able to follow the visit arrangements specified in the protocol during the trial period.

Exclusion criteria

Exclusion Criteria:

  • Expected survival time\<12 months;
  • Severe liver dysfunction (non heart disease induced or AST>3x ) and cirrhosis;
  • Pregnant or lactating women, or participants and their partners who plan to become pregnant during the trial period;
  • The researchers determined that other reasons were not suitable for participants in this experiment.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
1,000 participants (estimated)

Study arms

  • Experimental
    Experimental group

    Vicagrel loading followed by Maintenance dose

    Drug: Vicagrel

  • Active comparator
    Control group

    Clopidogrel loading followed by Maintenance dose

    Drug: Clopidogrel

Interventions

  • Vicagrel loading followed by Maintenance dose

  • Clopidogrel loading followed by Maintenance dose

06

What researchers measure

Primary outcomes

  1. The incidence of MACE

    Time frame: 6 month

07

Study locations

1 of 1 sites recruiting
  • General Hospital of Northern Theater Command of Chinese PLA
    Shenyang, Liaoning 110015, China
    Recruiting
    • Yaling Han, M.D. · Contact
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2024 (actual). Primary completion is estimated for Dec 2026, 27 months after the start.

Of 39 phase 3 interventional studies under Acute Coronary Syndrome, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 52. This study's planned 27 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 28, 2024
First posted
Aug 29, 2024
StartActual
Sep 6, 2024
Primary completionEst.
Dec 30, 2026
CompletionEst.
Dec 30, 2026
Last update
Jul 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06577519
Responsible party
Sponsor
First posted
Aug 29, 2024
Start date
Sep 6, 2024
Primary completion
Dec 30, 2026 (estimated)
Completion
Dec 30, 2026 (estimated)
Last update
Jul 27, 2026

Study contacts

Xiaojuan Lai
Contact
lai_xiaojuan@vcarepharmatech.com
15358160458

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sumecigrel

Start the discussion